Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04775082 · ClinicalTrials.gov registry record · Phase 3

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.

Active
Registry status
Phase 3
Development phase
78
Enrollment target
20
Study locations

NCT04775082: Active Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.

NCT04775082 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 78 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04775082, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
78 participants
Enrollment target
20
Study locations

Study Summary

The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.

Conditions Studied

Obesity

Interventions

  • DRUG Placebo
  • DRUG Liraglutide

Study Locations (20)

Other

  • UZ Brussel - Brussels
  • UZ Leuven - Kindergeneeskunde - Leuven
  • Mamc & Lnjp - New Delhi
  • Rambam MC - Department of Pediatrics A - Haifa
  • Schneider MC - Endrocrinology and Diabetes - Petah Tikva
  • Hospital Putrajaya - Putrajaya
  • Consultorio de Endocrinología y Pediatría - Puebla City
  • Hospital Da Luz S.A. - Lisbon
  • Hospital da Luz - Lisbon

Arizona

  • TMC Hlthcr Clin Res Office - Tucson

Colorado

  • Children's Hospital Colorado - Denver

Idaho

  • Solaris Clinical Research - Meridian

Louisiana

  • Pennington Biom Res Ctr - Baton Rouge

Maryland

  • Barry J. Reiner, MD LLC - Baltimore

Minnesota

  • University of Minnesota_CPOM - Minneapolis

New York

  • UBMD Peds-Div of Endo/Diabetes - Buffalo

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2021-03-04
Est. Completion 2027-01-15
Phase Phase 3

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04775082

The ClinicalTrials.gov registry entry for NCT04775082 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04775082 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT04775082 about?

NCT04775082 is a clinical study titled "SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity". The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or pla...

What is the current status of trial NCT04775082?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2021-03-04. Estimated completion is 2027-01-15.

What conditions does trial NCT04775082 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT04775082?

The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG).

Who is sponsoring clinical trial NCT04775082?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04775082 being conducted?

This trial has 20 study locations across Arizona, Colorado, Idaho, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.